Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Hematology · AL Amyloidosis

Standard of Care: Treatments and Care Teams

At a Glance

The standard of care for newly diagnosed AL amyloidosis is the DARA-CyBorD medication regimen, which quickly stops the production of toxic proteins. Because the disease is rare and affects multiple organs, seeking treatment from a multidisciplinary Center of Excellence is highly recommended.

AL amyloidosis is a time-sensitive condition. Because organ damage can progress rapidly, prompt initiation of treatment is critical [1][2]. Treating AL amyloidosis is a two-step process: first, you must stop the “factory” (the abnormal plasma cells) from making toxic proteins; second, you must support the organs as they slowly begin to heal [3][4].

The Standard of Care: DARA-CyBorD

The current “gold standard” for newly diagnosed patients is a combination therapy known as DARA-CyBorD [5][6]. This regimen typically involves:

  • Daratumumab (Dara): A monoclonal antibody that targets a specific protein (CD38) on the bad plasma cells. It is now commonly given as a quick subcutaneous injection (under the skin) rather than a lengthy IV infusion, which significantly improves quality of life [7][8].
  • Cyclophosphamide (Cy): A traditional chemotherapy drug.
  • Bortezomib (Bor): A targeted therapy that causes the abnormal cells to “clog up” and die.
  • Dexamethasone (D): A steroid that helps the other drugs work better and reduces inflammation.

Important Side Effects to Watch For:
While highly effective, these medications carry serious risks that require your vigilance [3][9].

  • Infection Risk: Daratumumab and cyclophosphamide significantly suppress your immune system. Infection is a major risk. You must report any fever, cough, or signs of illness to your team immediately [3][10].
  • Peripheral Neuropathy: Bortezomib can cause numbness, tingling, burning, or pain in your hands and feet. If you experience this, tell your doctor right away. The dose can be adjusted before the nerve damage becomes permanent [9][11].

The Role of Stem Cell Transplant

An Autologous Stem Cell Transplant (ASCT) is a procedure where your own healthy stem cells are collected, high-dose chemotherapy is given to “wipe out” the remaining plasma cells, and then your stem cells are returned to you [12][13].

The role of transplant is evolving. While it used to be the primary goal for every fit patient, modern drugs like daratumumab are so effective that the strategy is shifting [12][6]:

  • Immediate Transplant: Still recommended for some patients who are healthy enough to handle the procedure and want to ensure the deepest possible response early on [12][14].
  • Deferred (Delayed) Transplant: Because DARA-CyBorD works so well, many doctors now wait to see your response. If you achieve a “complete response” (CR) without a transplant, your doctor may suggest “collecting and protecting” your stem cells for use only if the disease returns in the future [12][15].

Why a Specialized Center Matters

AL amyloidosis is a rare, “multi-system” disease. A standard oncologist may only see one or two cases in their entire career. It is critical to seek care at a Center of Excellence for amyloidosis because [16][17]:

  1. Precision Staging: Specialized centers have access to the most accurate tests, like mass spectrometry and advanced cardiac imaging, ensuring you aren’t misdiagnosed [18][19].
  2. Multidisciplinary Expertise: You need a team that includes a hematologist (to treat the blood), a cardiologist (to manage heart involvement), and a nephrologist (to protect your kidneys) who all speak the same language regarding this disease [17][20].

If you cannot travel to a major center for every treatment, your local doctor can often partner with a specialist to co-manage your care [17].

Common questions in this guide

What is the standard treatment for newly diagnosed AL amyloidosis?
The current gold standard treatment is the DARA-CyBorD regimen. This combination therapy uses four different medications to stop abnormal plasma cells from producing toxic proteins, which allows your organs to begin healing.
Will I definitely need a stem cell transplant?
While stem cell transplants used to be standard for all fit patients, modern drugs have changed this approach. Many doctors now wait to see how you respond to initial medications like DARA-CyBorD before recommending a transplant.
What are the most important side effects of the DARA-CyBorD regimen?
Key side effects include a higher risk of infection due to a suppressed immune system and peripheral neuropathy from nerve damage. You should immediately report any signs of illness, numbness, or tingling to your doctor so they can adjust your care.
Why is it important to go to an amyloidosis Center of Excellence?
AL amyloidosis is a very rare disease that requires a specialized, multidisciplinary team of hematologists, cardiologists, and nephrologists working together. Specialized centers have the specific experience and advanced testing needed for accurate diagnosis and management.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do you work with a multidisciplinary team (cardiology, nephrology, etc.) that specializes specifically in AL amyloidosis?
  2. 2.Am I a candidate for the DARA-CyBorD regimen, and will the daratumumab be given as a subcutaneous injection?
  3. 3.What should I do if I start feeling numbness, tingling, or pain in my fingers and toes from the treatment?
  4. 4.If I achieve a 'complete response' with my initial treatment, do you still recommend a stem cell transplant right away?
  5. 5.What are my specific risks for infection, and what signs mean I should go straight to the emergency room?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Healthcare resource utilisation and costs associated with AL amyloidosis: a retrospective matched cohort study.

    Shen SP, Hou HA, Huang KC, et al.

    Scientific reports 2024; (14(1)):16915 doi:10.1038/s41598-024-65654-5.

    PMID: 39043721
  2. 2

    AL amyloidosis: Singapore Myeloma Study Group consensus guidelines on diagnosis, treatment and management.

    Tan M, Chen Y, Ooi M, et al.

    Annals of the Academy of Medicine, Singapore 2023; (52(11)):601-624 doi:10.47102/annals-acadmedsg.2023101.

    PMID: 38920149
  3. 3

    Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

    Kastritis E, Palladini G, Minnema MC, et al.

    The New England journal of medicine 2021; (385(1)):46-58 doi:10.1056/NEJMoa2028631.

    PMID: 34192431
  4. 4

    First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience.

    Jeryczynski G, Antlanger M, Duca F, et al.

    ESMO open 2021; (6(2)):100065 doi:10.1016/j.esmoop.2021.100065.

    PMID: 33667762
  5. 5

    AL Amyloidosis: Current Treatment and Outcomes.

    Locke M, Nieto M

    Advances in hematology 2025; (2025()):7280805 doi:10.1155/ah/7280805.

    PMID: 40226119
  6. 6

    AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review.

    Bianchi G, Zhang Y, Comenzo RL

    JACC. CardioOncology 2021; (3(4)):467-487 doi:10.1016/j.jaccao.2021.09.003.

    PMID: 34729520
  7. 7

    Primary systemic amyloidosis: A brief overview.

    Hughes MS, Lentzsch S

    Presse medicale (Paris, France : 1983) 2025; (54(1)):104267 doi:10.1016/j.lpm.2024.104267.

    PMID: 39672504
  8. 8

    Treatment Approach for Advanced Systemic Light Chain Amyloidosis: A Case Report.

    Hachem MAM, Nasreddine GM, Farhat S, et al.

    Cureus 2024; (16(8)):e65960 doi:10.7759/cureus.65960.

    PMID: 39221331
  9. 9

    Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.

    Blair HA

    Drugs 2022; (82(6)):683-690 doi:10.1007/s40265-022-01705-3.

    PMID: 35416593
  10. 10

    Thrombotic and bleeding complications in patients with AL amyloidosis.

    Fotiou D, Theodorakakou F, Spiliopoulou S, et al.

    British journal of haematology 2024; (204(5)):1816-1824 doi:10.1111/bjh.19331.

    PMID: 38321638
  11. 11

    Supportive Care in AL Amyloidosis.

    Cibeira MT, Ortiz-Pérez JT, Quintana LF, et al.

    Acta haematologica 2020; (143(4)):335-342 doi:10.1159/000506760.

    PMID: 32235118
  12. 12

    Role of Autologous Stem Cell Transplantation in Systemic Light Chain Amyloidosis.

    Parmar H, Doucette K, Vesole D

    Clinical lymphoma, myeloma & leukemia 2024; (24(11)):770-777 doi:10.1016/j.clml.2024.06.009.

    PMID: 39122638
  13. 13

    A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.

    Sharpley FA, Petrie A, Mahmood S, et al.

    British journal of haematology 2019; (187(5)):642-652 doi:10.1111/bjh.16143.

    PMID: 31410841
  14. 14

    Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time.

    Sidiqi MH, Aljama MA, Buadi FK, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(13)):1323-1329 doi:10.1200/JCO.2017.76.9554.

    PMID: 29558277
  15. 15

    Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis.

    Basset M, Milani P, Nuvolone M, et al.

    Blood advances 2020; (4(17)):4175-4179 doi:10.1182/bloodadvances.2020002219.

    PMID: 32886751
  16. 16

    Diagnosis and Treatment of AL Amyloidosis.

    Palladini G, Milani P

    Drugs 2023; (83(3)):203-216 doi:10.1007/s40265-022-01830-z.

    PMID: 36652193
  17. 17

    Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis.

    Kim D, Choi JO, Kim K, et al.

    International journal of heart failure 2020; (2(4)):231-239 doi:10.36628/ijhf.2020.0016.

    PMID: 36262171
  18. 18

    Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation.

    Dima D, Mazzoni S, Anwer F, et al.

    JCO oncology practice 2023; (19(5)):265-275 doi:10.1200/OP.22.00396.

    PMID: 36854070
  19. 19

    Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.

    Griffin JM, Rosenblum H, Maurer MS

    Circulation research 2021; (128(10)):1554-1575 doi:10.1161/CIRCRESAHA.121.318187.

    PMID: 33983835
  20. 20

    Screening for hereditary transthyretin amyloidosis in Bulgaria.

    Nakov R, Nakov V, Gospodinova M, et al.

    Medicine and pharmacy reports 2021; (94(Suppl No 1)):S8-S10 doi:10.15386/mpr-2218.

    PMID: 34527899

This page provides educational information about AL amyloidosis treatment options and standards of care. It is not a substitute for professional medical advice, and you should always consult your specialized care team regarding your specific treatment plan.

Get notified when new evidence is published on Primary systemic amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.